Acquiring Company
Korsana Biosciences
Acquired Company
Cyclerion Therapeutics
WalthamCambridgeBiotechnologyHealth CareTherapeuticsBiotechnologyHealthcareHealth CareTherapeuticsDescription
Korsana Biosciences has successfully completed its merger with Cyclerion Therapeutics, along with a $380 million funding round. The new company, continuing under the name Korsana, is now publicly traded on Nasdaq. This merger aims to enhance their focus on developing innovative treatments for neurodegenerative diseases.
Don't miss Korsana Biosciences's next move
Get an email the moment Korsana Biosciences makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Cyclerion Therapeutics?
Cyclerion Therapeutics was acquired by Korsana Biosciences, based in Waltham. The deal was reported on September 10, 2026. Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. Korsana Biosciences is privately held and operates in Biotechnology.
When did Korsana Biosciences acquire Cyclerion Therapeutics?
Korsana Biosciences's acquisition of Cyclerion Therapeutics was reported on September 10, 2026. Korsana Biosciences has successfully completed its merger with Cyclerion Therapeutics, along with a $380 million funding round. The new company, continuing under the name Korsana, is now publicly traded on Nasdaq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company. It is publicly traded (CYCN), operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.